Physician profile
Juan Velez Rivera
NPI 1740669993
$1,086.58
in general payments reported to CMS, 2019-2025
14 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $76.40 · 2021: $85.92 · 2022: $120 · 2023: $49.52 · 2024: $388 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $639.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $308.59 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $196.91 | 2019-2024 | Airsupra |
| Dexcom, INC. | $113.54 | 2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $111.61 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $71.59 | 2019-2022 | |
| Abbvie INC. | $56.86 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $53.87 | 2019-2020 | |
| Boston Scientific Corporation | $39.09 | 2025 | General - Angioplasty, Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.08 | 2023 | Jardiance |
| Eli Lilly Export S.A. Puerto Rico Branch | $24.95 | 2024 | Zepbound |
| Elucent Medical | $24.93 | 2025 | |
| Merck Sharp & Dohme LLC | $24.61 | 2025 | Capvaxive, Gardasil 9 |
| Chiesi USA, INC. | $18.15 | 2019 | |
| Pfizer Pharmaceuticals LLC | $15.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Velez Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.